Related Experiment Videos
Restoration of flow in acute coronary obstructive syndromes: consequences of different management strategies
1Department of Medicine, McGill University, Montreal, Quebec.
Insights
Immediate low-dose aspirin for acute myocardial infarction can save 1200 lives annually in Canada. Adding intravenous streptokinase may save over 1000 more lives, representing a cost-effective intervention for acute coronary syndromes.
Area of Science:
- Cardiology
- Public Health
Background:
- Acute coronary syndromes (ACS) require timely and effective management strategies.
- Recent therapeutic trials provide evidence for specific interventions in ACS.
- A nationwide review of ACS management is warranted based on current data.
Purpose of the Study:
- To evaluate the impact of immediate low-dose aspirin and intravenous streptokinase on mortality in acute myocardial infarction (AMI).
- To assess the cost-effectiveness of these interventions for ACS management.
- To provide recommendations for nationwide ACS treatment protocols.
Main Methods:
- Analysis of data from recent therapeutic trials on ACS management.
- Estimation of lives saved and costs associated with aspirin and streptokinase therapy.
- Review of evidence for thrombolytic treatment in acute unstable angina.
Main Results:
- Immediate low-dose aspirin for suspected AMI, continued for 1-6 months, is expected to save 1200 lives/year in Canada at negligible cost.
- Intravenous streptokinase infusion within 24 hours of onset can save an additional 1088 lives/year at approx. $11,000 per life.
- Evidence for thrombolytic agents other than streptokinase and for unstable angina remains uncertain.
Conclusions:
- Nationwide implementation of low-dose aspirin for suspected AMI is strongly indicated.
- Intravenous streptokinase offers significant survival benefits for AMI patients within the first 24 hours.
- Further research is needed for other thrombolytic agents and their role in acute unstable angina.
Abstract:
Although much necessary evidence is not yet available, there is sufficient information from recent therapeutic trials to necessitate a nationwide review of the management of acute coronary obstructive syndromes. On the basis of present information it is evident that, in addition to heparin, all patients suffering from suspected acute myocardial infarction should receive immediate low dose aspirin which should be continued for one to six months. This treatment, if generally applied, can be expected to save 1200 lives per year in Canada at negligible cost. Addition of intravenous streptokinase infusion to all patients (in whom there are no contraindications) available for treatment from 0 to 24 h from the onset, can be expected to save an additional 1088 lives at an additional cost of approximately $11,000 per life. Other thrombolytic agents involve additional cost and the gains in terms of mortality are not yet demonstrated. The evidence for thrombolytic treatment in acute unstable angina is still uncertain but the treatment of all cases with aspirin from the earliest possible moment is clearly indicated.